Opiate abuse is an epidemic in the United States. Drug overdose death rates have skyrocketed in the last decade, with death rates due to prescription opioid pain relievers quadrupling between 1999 and 2010. 1 This same time period also showed a nearly twofold increased risk in deaths due to heroin, a rate that then doubled again between 2010 and 2012. 1 Data regarding use are more difficult to obtain as such information usually relies upon self-report. In pregnancy, death due to illicit substances is relatively uncommon, but $4.4% of women report use of nonmedicinal drugs, with opioids noted to be the second most commonly abused substance. 2, 3 Much of this use is initiated as abuse of nonmedically indicated prescription pain pills, but heroin abuse is increasing in the setting of increased legislation limiting opiate prescriptions. Accordingly, the incidence of neonatal abstinence syndrome increased from 1.20 to 3.39 per 1,000 hospital births per year from 2000 to 2009.
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Beyond the risk of neonatal abstinence syndrome, there are several other complications and comorbidities associated with opioid use in pregnancy. Preterm birth, poor fetal growth, and intrauterine fetal demise are more common in the setting of opioid abuse, and the risks of withdrawal from narcotics have been well documented. 5 Drug abuse is also commonly associated with mental health disease, social problems, and financial issues. Beyond this, hepatitis C, hepatitis B, and human immunodeficiency virus (HIV) are commonly encountered in this population due to intravenous drug use and needle sharing. We present here another pregnancy complication associated with intravenous drug use, namely, that of red blood cell alloimmunization and hemolytic disease of the fetus and newborn (HDFN).
Methods and Materials
We present an observational case series of patients with red blood cell alloimmunization and a history of intravenous drug use identified at the Ohio State University (OSU) Wexner Medical Center between 2011 and December 1, 2015. Permission to retain and review patients' data was obtained from 
Results
Selected demographic data and pregnancy outcomes are outlined in ►Table 1. We have included patients who required in utero therapy, preterm birth due to concerns about fetal anemia, or neonatal therapy. Two additional cases were identified with low antibody titers (anti-C in one patient and anti-D in the other patient) and no diagnosis of HDFN. increased liver length, and an increased heart size with abnormal MCA Doppler assessment ((PSV of 76.87 cm/s consistent with 1.68 multiples of the median (MoM)). The patient was counseled at length and declined cordocentesis and intrauterine transfusion. She ultimately received antenatal corticosteroids and underwent a cesarean delivery for repetitive late fetal heart rate decelerations, delivering a 1,995-g male neonate. The neonate had an initial hemoglobin level of 10.0 g/dL at the time of delivery and developed significant hyperbilirubinemia soon thereafter. He underwent two exchange transfusions and received intravenous immunoglobulin (Carimune 6%) therapy three times during his hospital course.
Case 2
Patient 2 was a 24-year-old G2P0101 who presented at our institution at 29 0/7 weeks with hydrops fetalis secondary to alloimmunization to Rh(D) red blood cell antigens. Her obstetric Table 1 Selected demographic data and outcomes 
Discussion
We present here a pregnancy complication owing to intravenous drug use, specifically the occurrence of red blood cell alloimmunization and HDFN. This is a potentially serious complication with implications for both the patient and the fetus/neonate. In the only other reported case series of four women (five pregnancies) with alloimmunization due to needle sharing, outcomes were very poor, with hydrops fetalis identified in four of the five fetuses and only two of the five babies surviving to delivery. 7 With up-to-date monitoring and treatment, however, we obtained excellent outcomes in this population. The patients presented here developed significant HDFN, requiring intrauterine transfusion, an indicated preterm birth, and/or neonatal therapy, but they all delivered a live-born, healthy neonate. An injection of as little as 0.5 to 1.0 mL of D-positive red blood cells will cause antibody formation in 50% of Rh-negative recipients. 8 In fact, the majority of cases of alloimmunization in pregnancy occur due to fetomaternal hemorrhage of less than 0.1 mL. 9 It has been estimated that 41% of intravenous drug users report sharing needles and/or paraphernalia, 10 and the state of Ohio currently does not endorse a formal needle-exchange program. Red blood cell alloimmunization has greatly decreased since the introduction of RhIG as part of routine prenatal/ postpartum care. The occurrence of alloimmunization to the D antigen decreases from 16% in untreated women after two pregnancies to 0.1% with appropriate use of RhIG in Rh-negative patients with incompatible fetuses.
9 Patients exposed to incompatible red blood cell antigens via intravenous drug abuse obviously do not benefit from this preventative measure.
In this case series, we excluded all patients who could have been alloimmunized in another manner, although the major weakness of this case series is that we cannot completely eliminate other causes for sensitization. This issue is particularly applicable as this patient population may not always report an accurate history. For example, patient 3 denied a history of sharing needles, but her hepatitis C infection suggested otherwise.
Not only is intravenous drug use a previously unreported mechanism for HDFN, but also this patient population presents several other issues that must be considered when deciding on treatment options. First of all, patients with a history of opiate abuse frequently have financial and social issues, factors that can greatly impact their ability to comply with recommendations for frequent visits. For example, these patients may even be incarcerated during their pregnancy. Second, anesthetic options may be complicated at the time of procedures such as cordocentesis or intrauterine transfusion due to patients' altered perception of pain and resistance to the effects of opioid pain relievers. Finally, hepatitis C, hepatitis B, and/or HIV infections are relatively common in this population. While such infections are not contraindications to performing an amniocentesis, cordocentesis, or intrauterine transfusion, there are case reports of vertical transmission attributed to such procedures. 11, 12 Infected patients must be counseled about this risk. With development of concerns for HDFN at an early gestational age (i.e., <32-34 weeks of gestation), the benefits of intrauterine transfusion and prolonged gestation likely outweigh the risk of maternal-to-child transmission, but delivery may be a more appropriate intervention as the gestational age increases.
Screening for substance abuse is recommended as part of routine prenatal care, and antibody screening is included in routine prenatal laboratory testing. While no specific additions to care are recommended based on the information presented here, clinicians should be aware of the potential for alloimmunization to red blood cell antibodies as yet another negative outcome from intravenous drug abuse.
